VCEL News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

VC

Mkt Cap

$2.05B

Volume

547.81K

Next Earnings

November 5th

Loading chart

VC

VCELVericel Corporation

VCEL

Pay with—

Available Balance0.00

VC

Mkt Cap

$2.10B

Volume

547.81K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase ProgramVericel Corporation reported strong Q2 2026 results with total revenue increasing 22% to $77.5 million and MACI revenue growing 23%. The company raised its full-year 2026 revenue guidance to $330-$340 million and announced a $200 million share repurchase program. Net income reached $2.2 million with free cash flow of $14.3 million, demonstrating sustained profitability and cash generation.GlobeNewswire Inc. · Jul 30, 2026

Global Stem Cell Therapy Market Set to Flourish at a CAGR of ~11% by 2034 Owing to the Technological Advancements and Favorable Regulations | DelveInsightThe global stem cell therapy market is projected to grow from USD 21.9 billion in 2025 to USD 58.5 billion by 2034, driven by technological advancements, favorable regulations, and rising demand for regenerative medicine treatments for chronic diseases. North America leads the market with 48.87% share, while Asia-Pacific emerges as a key growth engine with recent approvals of iPSC-based therapies in Japan.GlobeNewswire Inc. · May 5, 2026

Vericel Announces Preliminary 2025 Financial Results and Business UpdatesVericel Corporation announced preliminary 2025 financial results with total revenue of $276 million, driven by MACI revenue of $239.5 million. The company achieved 23% fourth quarter revenue growth, 74% gross margin, and 26% adjusted EBITDA margin, with GAAP net income profitability for the second consecutive year. The company completed its MACI sales force expansion and initiated a clinical study for MACI Ankle, while maintaining $200 million in cash with no debt.GlobeNewswire Inc. · Jan 13, 2026

Brown Capital Discloses $31 Million Sale of Vericel Stock as Small-Cap Biotech Reports EarningsBaltimore-based Brown Capital Management sold 861,020 shares of Vericel Corporation for approximately $31 million in Q3 2025, reducing its stake while the biotech company reported strong quarterly revenue growth of 17%.The Motley Fool · Nov 6, 2025

MediWound Revenue Jumps 43% in Q2MediWound reported a 43% quarterly revenue increase to $5.7 million, improved gross margins, and advanced its Phase III EscharEx trial while establishing strategic partnerships with wound care leaders.The Motley Fool · Aug 14, 2025

Vericel Q2 Revenue Jumps 20%Vericel reported Q2 2025 revenue growth of 20% to $63.2 million, driven by strong MACI cartilage repair franchise performance. The company expanded gross margins to 74% and narrowed net loss per share, while preparing for potential market expansion into ankle cartilage repair.The Motley Fool · Aug 5, 2025

Vericel Reports Second Quarter 2024 Financial ResultsVericel Corporation reported strong financial results for the second quarter of 2024, with record revenue, MACI revenue growth, and significant margin expansion. The company also provided an update on the progress of its NexoBrid launch and raised its full-year profitability guidance.GlobeNewswire Inc. · Aug 1, 2024

Global Regenerative Medicine Market Size To Worth USD 349.93 Billion By 2033 | CAGR of 27.06%The global regenerative medicine market is expected to grow from $31.90 billion in 2023 to $349.93 billion by 2033, driven by advancements in cell therapy, stem cell therapies, and tissue engineering. The musculoskeletal disorders segment is the fastest-growing application area.GlobeNewswire Inc. · Jul 30, 2024

Vericel corp chief legal officer sells $782,700 in company stock - Investing.comVericel Corp's Chief Legal Officer, Sean C. Flynn, has sold $782,700 worth of company stock as part of a prearranged trading plan. The transaction comes amid the company's strong financial performance and positive analyst coverage.Investing.com · Jul 18, 2024

Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Truist Securities MedTech Conference at 2:30 p.m. ET on Tuesday, June 18, 2024.GlobeNewswire Inc. · Jun 11, 2024

to start trading

VC

VCELVericel Corporation

VCEL

Pay with—

Available Balance0.00

Your PositionYou don't own any VCEL yet.

Related Tickers

Earnings